FLT3 and acute myeloid leukemia: Surface-localised mutant FLT3 in TKI-treated cells can be targeted by bispecific FLT3-CD3 antibodies for T-cell-mediated cytotoxicity, shown to be effective in FLT3 ITD-positive AML cell lines, patient-derived xenograft cells, and primary patient samples [19].